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Every company wants a drug like 
Taxol. Bristol-Myers Squibb sold 
$329 million of the anticancer agent 
in the first quarter of 1999 alone. 
Now Cytokinetics, Inc. (South San 
Francisco, California) is seeking a 
new, improved Taxol. Their approach 
is unique. Instead of aiming at 
microtubules, the cellular train tracks 
attacked by Taxol and a slew of 
similar anticancer compounds, 
Cytokinetics is targeting all the other 
proteins of the cell’s cytoskeleton. 
The company claims that these new 
targets will be more specific to the 
disease than the ubiquitous 
microtubules, thus reducing toxicity. 
The three filament systems of the 
cytoskeleton - actin, microtubules, 
and intermediate filaments - criss- 
cross the cell and give the cell its 
shape and mechanical strength. But 
the cytoskeleton is no longer seen 
simply as a rusty neglected scaffolding. 
Dynamic filaments are integral to cell 
division, movement and signaling in 
normal and diseased cells. “Basically 
the cytoskeleton is involved in most of 
the important things that the cell 
does,” says Larry Goldstein, a biologist 
at the University of California, San 
Diego, and one of the founders of 
Cytokinetics. An explosion in 
knowledge about the cytoskeleton - 
the identification of new components 
and determination of their function - 
has given Cytokinetics the raw materials 
it needs. “Right now there’s a richness 
of understanding of the role of the 
cytoskeleton,” says Cytokinetics co- 
founder and CEO James Sabry. “That 
for us represented a real opportunity.” 
Friendly beginnings 
Sabry is a young but confident 
newcomer to the world of business. 
He started his scientific career with a 
brief stay at Roche in Switzerland 
before heading to graduate school and 
medical school at the University of 
California at San Francisco, where he 
met Ron Vale, another Cytokinetics 
co-founder. Next came a postdoctoral 
fellowship with the final Cytokinetics 
co-founder: Jim Spudich of Stanford 
University (Palo Alto, California). 
After three years of business 
training, Sabry was eager to 
commercialize some science. “I’m 
fascinated by how biology and 
medicine intersect, and I’ve always 
had an inner entrepreneur,” he says. 
“The opportunity to build a new 
company in an area that I think has 
great opportunity was too much to 
pass up.” 
The cytoskeleton has proven to be 
a profitable drug target. But can it 
be more intelligently exploited? 
The scientific co-founders were 
happy to put someone else in charge. 
“The investors asked ‘which one of 
you is going to pull a McKnight?’ but 
none of us were wanting to leave 
academia,” says Goldstein. “James is 
very entrepreneurial, and he has the 
academic and medical background. 
Plus the four of us have worked 
together. That makes it fun as well 
as productive.” 
Let the screens begin 
The company structure is a 
combination of drug discovery and 
informatics, with the informatics 
providing some short-term income. 
The company started operations in 
July 1998, and is already doing high- 
throughput screening against purified 
proteins, including seven anticancer 
targets, six cardiovascular targets and 
one fungal target. Cytokinetics has 
small molecule hits for all the targets, 
and some of the anticancer hits work 
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against cells in vitro. Sabry is not 
disclosing the details of the screening 
method, but he says that it can assay 
up to 120,000 compounds in one day. 
The first major focus is cancer 
and, more specifically, kinesin 
proteins. Kinesins are motors that 
run along microtubules. They deliver 
cargo, build the mitotic spindle, and 
distribute chromosomes into two 
daughter cells. The kinesins have a 
well-defined activity that can be 
assayed, and some of them are 
mitosis specific, unlike microtubules. 
The possibilities do not stop with 
kinesin. Over 5000 cytoskeletal 
proteins may exist in man, and 
inhibitory drugs exist only for 
tubulin, the building block of 
microtubules. “The anti-microtubule 
drugs are a proof of principle,” says 
Spudich, “but [the microtubule] is 
probably the worst of the 5000 things 
you’d want to target.” 
Old drugs and new targets 
Still, Tax01 and taxotere (a chemical 
relative of Tax01 made by Rhone- 
Poulenc Rorer (RPR)) are both 
blockbuster drugs, and close behind 
them are developmental anti- 
microtubule compounds such as the 
epothilones, cryptophycins, 
dolastatins, and discodermolide. 
“Anti-microtubule drugs are still seen 
as a deep well where we are still 
getting good new compounds,” says 
Dan Sackett of the National Institutes 
of Health (NIH; Bethesda, Maryland). 
“There’s a tremendous amount of 
activity in this area,” says Susan 
Horwitz (Albert Einstein College of 
Medicine, Bronx, New York). In 1979, 
Horwitz determined the mechanism 
of action of Taxol. Now she says 
researchers are hoping to make 
smaller compounds that can work in 
oral formulations and against different 
types of tumors. “All these things,” 
she says, “are in the making.” 
Cecile Combeau, a senior scientist 
at RPR, says that RPR is trying to 
extend the indications for taxotere 
and to find compounds that are not 
disposed of by resistance proteins. 
“Then I think that’s the end of 
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tubulin as a target,” she says. “We are 
more interested in other approaches 
- apoptosis, angiogenesis, signal 
transduction and mitotic kinases.” 
Combeau says that RPR has not 
done targeted assays against 
individual cytoskeletal proteins other 
than tubulin. “People here think that 
targeting these proteins would lead to 
the same toxic effects seen with anti- 
microtubule agents,” she says. 
Combeau believes that finding 
kinesin inhibitors will be easy. The 
harder task will be finding inhibitors 
that are specific to mitotic kinesins, 
so kinesins that drive secretion and 
transport in nondividing cells are not 
affected. Sabry says, “we’ve already 
done that, and [the compounds] are 
remarkably specific.” 
The company’s first kinesin 
inhibitor was adociasulfate-2 (AS-Z), 
which Goldstein isolated in 1988 
from a marine sponge. AS-Z inhibits 
the kinesin-microtubule interaction 
rather than the kinesin active site. It 
is not a drug candidate, as it inhibits 
a number of different kinesins 
equally, and is cell impermeable. 
A mitosis-specific drug would 
eliminate one significant side effect 
of anti-microtubule drugs: the 
neurotoxicity that is dose limiting for 
the vinca alkaloids. But for taxotere 
the dose-limiting side effect is a 
reduction in neutrophil levels 
presumably caused by mitosis 
inhibition. A kinesin drug may run 
into similar problems, and NIH’s 
Sackett says that in the meantime 
the problem may be bypassed by a 
tubulin drug with improved tissue 
distribution properties. All anticancer 
drugs, he notes, are at the mercy of 
the poorly understood issue of tissue 
distribution. 
The biggest question of all is 
whether any kinesin inhibitor will 
work as an anticancer drug. “They 
are really taking a chemical genetic 
approach in that they are taking a 
nonvalidated target, screening for 
inhibitors, and then seeing if 
inhibitors do anything,” says Randy 
King (Harvard Medical School, 
Boston, Massachusetts), who is 
screening in frog extracts for anti- 
mitotic compounds that do not affect 
microtubules. Goldstein did show 
that AS-2 inhibits mitosis in fruit 
flies and, although it is a long way 
from flies to cancer, Sabry says, 
“we’re way ahead of fruit flies now.” 
Beyond kinesin 
The founders of Cytokinetics do not 
see the cytoskeleton as limiting their 
vision. “I believe the cytoskeleton 
will touch on almost all diseases at 
some level,” says Spudich. “Nothing 
is really ruled out in my mind.” 
Targets other than kinesin are 
being selected based on existing cell 
biological knowledge, and Sabry 
claims the company has targets that 
are both mitosis specific and cancer 
specific. For some targets 
Cytokinetics has been the first to 
clone the human version of the gene, 
and so can obtain a composition of 
matter patent. Spudich says the 
company will be watching the 
information emerging from the 
human genome project for further 
target ideas. 
In its cardiovascular program, 
Cytokinetics is hoping to find an 
activator of muscle contraction to aid 
in congestive heart failure. Although 
activators are notoriously hard to 
find, an inhibitor of an inhibitory 
protein may work just as well. The 
focus in the antifungal project will be 
on cytoskeletal elements that differ 
between the host and fungal cells, 
with a special emphasis on organelle 
transport and r‘ilamentous growth. 
The latter is essential for the 
virulence of fungi such as Candida, 
and is also an interest of a start-up 
called Microbia, Inc. (Cambridge, 
Massachusetts). 
An informatics back-up 
Cytokinetics is developing a cell- 
based screening and database system 
called Cytometrix to prioritize its 
own compounds and to spread the 
company’s financial risk. Cytometrix 
detects changes in the cell cycle, 
protein trafficking, apoptosis, 
adhesion and endocytosis in response 
to drug treatment, at a rate of 1500 
samples per day. The speed is 
projected to increase tenfold by the 
end of 1999. “There has to be 
something between getting hits and 
[testing in] animals,” says Sabry. 
“Cytometrix is a post high- 
throughput screening filter, before 
you go to animals.” 
Cytometrix will be offered as a 
contract service, starting in 2000 or 
2001. The company is building a 
database of cell responses to 
chemicals with known mechanisms 
of action, and Sabry says the 
database should be a good predictor 
of the mechanism of action of novel 
compounds. Similar concepts are 
used in transcriptional profiling using 
DNA chips. “We see these 
approaches as complementary,” says 
Sabry. “If I were a Merck or Pfizer I 
would want both.” 
The chips are best at testing the 
response of thousands of genes to 
one or a few conditions. There are 
fewer read-outs from Cytometrix, 
but it can test thousands of samples. 
Furthermore, says Sabry, “the 
transcription read-out is a surrogate 
for the biology, whereas we are 
measuring the biology directly.” 
Competition may be heavy in 
phenotype testing. Cellomics, Inc. 
(Pittsburgh, Pennsylvania) has a 
similar high-throughput system (see 
CLem. Bid 5, R20.5). Michael Sheetz 
(Duke University, Durham, North 
Carolina) likes the database idea, but 
says that “the question is if everyone 
and their brother is going to try that 
approach.” 
The founders of Cytokinetics may 
have chosen two areas likely to attract 
many other companies, but they 
remain confident of their ability to 
stay ahead. “The amazing thing is 
that there weren’t already 30 
companies doing this,” says Spudich. 
“I think there will be plenty of people 
entering this area, but quite frankly I 
think there is plenty of room.” 
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